Related Experiment Video
Updated: May 5, 2026
09:43
Measurement of Heme Synthesis Levels in Mammalian Cells
Published on: July 9, 2015
12.0K
P2 Receptor Antagonists Rescue Defective Heme Content in an In Vitro SLC25A38-Associated Congenital Sideroblastic
Antonella Santoro1, Silvia De Santis1, Ferdinando Palmieri1,2,3
1Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, 70125 Bari, Italy.
International Journal of Molecular Sciences
|January 8, 2025
Summary
Mutations in the SLC25A38 gene cause congenital sideroblastic anemia (CSA). P2 receptor antagonists show promise for treating this severe anemia by improving cellular iron and heme levels.
Area of Science:
- Biochemistry
- Genetics
- Hematology
Background:
- Congenital sideroblastic anemia (CSA) is a severe genetic disorder.
- Mutations in the SLC25A38 gene cause the second most common form of CSA.
- No effective treatments currently exist for SLC25A38-associated CSA.
Purpose of the Study:
- To develop and characterize a cellular model for SLC25A38-associated CSA.
- To identify potential therapeutic targets for this condition.
Main Methods:
- Developed a K562 erythroleukemia cell line with reduced SLC25A38 protein expression (A38-low cells).
- Characterized the A38-low cell model for CSA features.
- Investigated the effect of extracellular pyridoxal 5'-phosphate (PLP) and P2 receptor antagonists on A38-low cells.
Main Results:
- The A38-low cell model recapitulated key CSA features: reduced heme, impaired mitochondrial respiration, increased mitochondrial iron, elevated ROS, and oxidative stress sensitivity.
- Extracellular PLP and P2 receptor antagonists rescued altered parameters in A38-low cells.
- P2 receptor antagonists increased heme content from ~50% to ~80% in A38-low cells.
Conclusions:
- Targeting P2 receptors represents a potential therapeutic strategy for SLC25A38-associated CSA.
- This study reveals a novel role for extracellular PLP and P2 receptor antagonists in managing CSA-related cellular defects.
